Predicted to enable long-chain-acyl-CoA dehydrogenase activity and medium-chain-acyl-CoA dehydrogenase activity. Predicted to be involved in long-chain fatty acid metabolic process; medium-chain fatty acid metabolic process; and mitochondrial respiratory chain complex I assembly. Predicted to be located in dendrite; mitochondrial membrane; and nucleus. Human ortholog(s) of this gene implicated in nuclear type mitochondrial complex I deficiency 20. Orthologous to human ACAD9 (acyl-CoA dehydrogenase family member 9); PARTICIPATES IN fatty acid beta degradation pathway; INTERACTS WITH (+)-schisandrin B; 2,2',5,5'-tetrachlorobiphenyl; 2,4,6-trinitrotoluene.
ACAD-9; acyl-CoA dehydrogenase family member 9, mitochondrial; acyl-Coenzyme A dehydrogenase family, member 9; complex I assembly factor ACAD9, mitochondrial; Nyggf2
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACAD9 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACAD9 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACAD9 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACAD9 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACAD9 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACAD9 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ACAD9 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACAD9 mRNA
[Vehicle Emissions results in increased abundance of Particulate Matter] inhibits the reaction [Oleic Acid results in increased expression of ACAD9 mRNA]